The idea of patent protection in the pharmaceutical industry is a joke.
Increasingly, drug companies are not investing in R&D proportional to the profits they earn from the drugs they bring to market, despite their protests to the contrary. Instead, many have figured out that it’s simpler and safer from a financial perspective to either buy the rights to drugs developed by others and raise the prices many times over, as with Sovaldi, or to obtain a medication already in existence and, using monopolistic control, raise the price as much as 500% or more, as in the case of the EpiPen.
As a consequence, the patent protection process now primarily serves the drug companies, most often not on behalf of the American people, but, rather, at their expense.
Patent protection effectively grants the pharmaceutical industry a monopoly, regardless of the human consequences.